Helix BioPharma: Top 10 Undervalued Biotechnology Industry Stocks on TSE (HBP)
Helix BioPharma is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Biotechnology: Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drugrelated technologies. Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| RVX-T | Resverlogix | 0.23 | 0.35 | 0.11 (48.01) | 25,106 | 58.6 | 0 | 0 |
| APS-T | Aptose Biosciences | 0.89 | 2.71 | 1.82 (204.05) | 15,869 | 82.1 | 0 | 0 |
| REUN-T | Reunion Neuroscience | 3.32 | 5.52 | 2.2 (66.4) | 19,463 | 38.6 | 0 | 0 |
| AEZS-T | AEterna Zentaris | 6.16 | 10.99 | 4.83 (78.37) | 2,224 | 29.9 | 0 | 0 |
| APLI-T | Appili Therapeutics | 0.06 | 0.11 | 0.05 (75.47) | 87,171 | 5.5 | 0 | 0 |
| MBX-T | Microbix Biosystems | 0.53 | 0.66 | 0.13 (25.19) | 39,539 | 76 | 0 | 26.5 |
| MDNA-T | Medicenna Therapeutics | 1.14 | 1.31 | 0.17 (14.56) | 58,837 | 64 | 0 | 0 |
| HBP-T | Helix BioPharma | 0.26 | 0.31 | 0.05 (20.83) | 25,379 | 37.6 | 0 | 0 |
| BCT-T | BriaCell Therapeutics | 10.9 | 18.35 | 7.45 (68.32) | 6,558 | 167.4 | 0 | 0 |
| IPCI-T | IntelliPharmaCeutics Intl | 0.11 | 0.22 | 0.11 (95.96) | 3,165 | 3.6 | 0 | 0 |
More about Helix BioPharma
All data provided as-at market close September 15, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Helix BioPharma Helix BioPharma Corp is a biopharmaceutical company mainly focused in the field of cancer therapy. The Company is actively developing products for the treatment and prevention of cancer based on its proprietary technologies. Helix BioPharma is listed under HBP on the Toronto Stock Exchange.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
